Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
B-cell lymphoma
Biotech
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Cullinan Therapeutics, as the biotech will now be known, is switching the focus of its CD19xCD3 T-cell engager to lupus.
James Waldron
Apr 16, 2024 10:05am
Oncternal reports patient death in CAR-T dose-escalation study
Dec 28, 2023 10:52am
Cargo, undeterred by market challenges, seeks $281M IPO
Nov 10, 2023 10:00am
Caribou heads 'where the puck is going' with cell therapy plan
Jun 6, 2023 2:25pm
ASH: Should existing BTKs worry about Lilly's newcomer?
Dec 12, 2022 5:30pm
FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial
Aug 18, 2022 11:23am
